Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Bob Lane, a prostate most cancers survivor on Erleada (apalutamide), shares how an surprising prognosis shifted his mindset.What began as a diverticulitis concern...
Trying forward, some of the promising advances in myeloma therapy is T cell-directed remedy. Myeloma is influenced not solely by the cancerous plasma...
